Marc D. Messier, PhD

Director Clinical Strategy
VALNEVA GMBH, France

Disclosure(s): SOBI: Advisor/Consultant; Valneva: employee, Ownership Interest

Poster(s):

• (P-599) 6-Valent, OspA-Based VLA15 Lyme Disease Vaccine Candidate Against Lyme Borreliosis in a Healthy Pediatric and Adult Study Population: A Phase 2 Study Update
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT